[{"quiz_id": "20251225T234023630Z_kimi-k2-thinking_seed133", "question_id": "20251225T234023630Z_kimi-k2-thinking_seed133-001", "question": "A 58-year-old man undergoes pancreaticoduodenectomy for a 2.5 cm pancreatic head adenocarcinoma. On postoperative day 3, his closed-suction drain has serous output of 25 mL/24 hours. Drain fluid amylase is 1,200 U/L (serum amylase 150 U/L). He is afebrile, hemodynamically stable, with soft abdomen and no leukocytosis. What is the most appropriate next step in management?", "options": ["Remove the drain", "Keep the drain and start octreotide", "Obtain contrast-enhanced CT of abdomen", "Keep the drain and discharge to home", "Return to operating room for exploration"], "answer": "A", "answer_index": 0, "explanation": "The 2016 ISGPS update defines a 'biochemical leak' as drain fluid amylase >3x serum on POD 1-3 with output <30 mL/day and no clinical sequelae, which can be managed by drain removal. Grade B fistula requires output >30 mL/day or clinical impact. The high amylase alone does not mandate retention if output remains low and the patient is clinically well.", "generator_model": "kimi-k2-thinking", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "General Surgery", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: Postoperative day 3 after pancreaticoduodenectomy, low drain output (25 mL/24 hours), elevated drain amylase (1,200 U/L, >3x serum 150 U/L), but patient afebrile, hemodynamically stable, soft abdomen, no leukocytosis—indicating biochemical leak without clinical impact per ISGPS criteria. Main logical issue(s), if any: None; stem provides sufficient details to discriminate options without contradictions or underspecification, supporting A as uniquely best (remove drain for low-output biochemical leak in well patient). Alternatives are inferior: B adds unnecessary octreotide; C pursues unneeded imaging; D retains drain against guidelines; E is overly aggressive. Main medical accuracy issue(s), if any: None; aligns precisely with 2016 ISGPS definitions distinguishing biochemical leak (manage conservatively, including early drain removal) from grade B/C fistulas requiring intervention. Item reflects current standards, avoiding outdated grade A terminology. Minimal fix: None required; item is already unambiguous and accurate, though optionally add 'biochemical leak' explicitly in rationale for clarity if desired.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: Postoperative day 3 after pancreaticoduodenectomy, low drain output (25 mL/24 hours), elevated drain amylase (1,200 U/L, >3x serum 150 U/L), but patient afebrile, hemodynamically stable, soft abdomen, no leukocytosis—indicating biochemical leak without clinical impact per ISGPS criteria. Main logical issue(s), if any: None; stem provides sufficient details to discriminate options without contradictions or underspecification, supporting A as uniquely best (remove drain for low-output biochemical leak in well patient). Alternatives are inferior: B adds unnecessary octreotide; C pursues unneeded imaging; D retains drain against guidelines; E is overly aggressive. Main medical accuracy issue(s), if any: None; aligns precisely with 2016 ISGPS definitions distinguishing biochemical leak (manage conservatively, including early drain removal) from grade B/C fistulas requiring intervention. Item reflects current standards, avoiding outdated grade A terminology. Minimal fix: None required; item is already unambiguous and accurate, though optionally add 'biochemical leak' explicitly in rationale for clarity if desired.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251225T234023630Z_kimi-k2-thinking_seed133", "question_id": "20251225T234023630Z_kimi-k2-thinking_seed133-002", "question": "A 65-year-old man is diagnosed with high-grade T1 urothelial carcinoma of the bladder, 3 cm solitary lesion without carcinoma in situ. His EORTC risk score is 8. He is scheduled to begin intravesical BCG immunotherapy. What is the optimal evidence-based regimen?", "options": ["Induction only (6 weekly instillations)", "Induction plus 1-year maintenance", "Induction plus 3-year maintenance using Tice strain", "Induction plus 3-year maintenance using Connaught strain with first maintenance dose at 8 weeks", "Induction plus 2-year maintenance"], "answer": "D", "answer_index": 3, "explanation": "An EORTC score of 8 classifies high-risk disease mandating 3-year maintenance BCG. The Connaught strain demonstrates superior recurrence-free survival compared to Tice strain in meta-analyses. Maintenance must commence 8 weeks after induction completion. This regimen reduces recurrence by 37% compared to 1-year maintenance and is the standard of care for high-risk patients.", "generator_model": "kimi-k2-thinking", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Urology", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: M (secondary U). Verdict on keyed answer: Not uniquely determinable. The clinical problem asks for the optimal evidence-based BCG regimen for a 65-year-old with high-grade T1 bladder urothelial carcinoma, 3 cm solitary lesion, no CIS, and EORTC progression risk score of 8, indicating high-risk NMIBC. Key stem clues: high-grade T1 stage, lesion size, absence of CIS, EORTC score 8 supporting high-risk classification warranting induction plus 3-year maintenance BCG per guidelines (e.g., AUA/EAU). These drive toward options C or D as best, but fail to uniquely distinguish due to no mention of strain efficacy or exact maintenance timing. Main logical issue: Underspecified stem omits critical details on BCG strain differences or timing, leading to multiple defensible answers (C and D both provide 3-year maintenance, equally reasonable without stem clues favoring Connaught or 8-week start). Alternatives: A inadequate for high-risk; B/E shorter duration suboptimal; keyed D assumes unstated superiority. Main medical accuracy issues: Keyed regimen aligns with evidence for 3-year maintenance reducing recurrence, but Connaught superiority is based on some meta-analyses, not universal guideline consensus; 8-week timing approximates SWOG protocol but not precisely standard (typically ~3 months post-induction). Minimal fix: Add to stem 'Recent meta-analyses demonstrate superior recurrence-free survival with Connaught over Tice strain' to make D uniquely best.\",\n  \"medical_accuracy_score\": 3,\n  \"logical_validity\": false,\n  \"logical_false_reason\": \"M\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (secondary U). Verdict on keyed answer: Not uniquely determinable. The clinical problem asks for the optimal evidence-based BCG regimen for a 65-year-old with high-grade T1 bladder urothelial carcinoma, 3 cm solitary lesion, no CIS, and EORTC progression risk score of 8, indicating high-risk NMIBC. Key stem clues: high-grade T1 stage, lesion size, absence of CIS, EORTC score 8 supporting high-risk classification warranting induction plus 3-year maintenance BCG per guidelines (e.g., AUA/EAU). These drive toward options C or D as best, but fail to uniquely distinguish due to no mention of strain efficacy or exact maintenance timing. Main logical issue: Underspecified stem omits critical details on BCG strain differences or timing, leading to multiple defensible answers (C and D both provide 3-year maintenance, equally reasonable without stem clues favoring Connaught or 8-week start). Alternatives: A inadequate for high-risk; B/E shorter duration suboptimal; keyed D assumes unstated superiority. Main medical accuracy issues: Keyed regimen aligns with evidence for 3-year maintenance reducing recurrence, but Connaught superiority is based on some meta-analyses, not universal guideline consensus; 8-week timing approximates SWOG protocol but not precisely standard (typically ~3 months post-induction). Minimal fix: Add to stem 'Recent meta-analyses demonstrate superior recurrence-free survival with Connaught over Tice strain' to make D uniquely best.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251225T234023630Z_kimi-k2-thinking_seed133", "question_id": "20251225T234023630Z_kimi-k2-thinking_seed133-003", "question": "A 72-year-old woman with metastatic melanoma on combination ipilimumab/nivolumab develops six watery stools daily. Laboratory studies show AST 180 U/L (upper limit of normal 40), ALT 220 U/L, and normal bilirubin. Colonoscopy reveals ulcerative colitis-like changes. What is the next step in management?", "options": ["Start prednisone 1 mg/kg plus infliximab 5 mg/kg", "Start prednisone 1 mg/kg plus vedolizumab 300 mg", "Start prednisone 1 mg/kg; if no improvement in 3-5 days add vedolizumab", "Hold immunotherapy and observe", "Start mycophenolate mofetil 1 g twice daily"], "answer": "C", "answer_index": 2, "explanation": "Grade 3 immune-related colitis with concurrent grade 2 hepatitis requires high-dose steroids (1-2 mg/kg prednisone). Infliximab is contraindicated in grade ≥2 hepatitis due to hepatotoxicity risk. Vedolizumab is the preferred second-line agent for steroid-refractory colitis without hepatic toxicity, but should be added only after 3-5 days of steroid failure rather than empirically.", "generator_model": "kimi-k2-thinking", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Medical Oncology", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. The clinical problem is determining the next management step for a patient with metastatic melanoma on ipilimumab/nivolumab presenting with immune-related colitis and concurrent hepatitis. Key stem clues include six watery stools daily (indicating grade 3 colitis), AST 180 U/L and ALT 220 U/L with normal bilirubin (grade 2 hepatitis), and colonoscopy showing ulcerative colitis-like changes. These drive a unique best answer: initiate high-dose prednisone (1 mg/kg), adding vedolizumab if no improvement in 3-5 days, as infliximab is contraindicated due to hepatotoxicity risk in concurrent hepatitis, per ASCO/NCCN guidelines. The most likely diagnosis is immune checkpoint inhibitor-induced colitis and hepatitis. Keyed answer C fits precisely, requiring no unstated assumptions beyond standard toxicity grading. Alternatives: A is worse due to infliximab's hepatic risk; B adds vedolizumab empirically, contrary to stepwise guidelines; D is inadequate for grade 3 severity without steroids; E uses mycophenolate, which is not first-line for colitis and more suited for refractory hepatitis. No main logical issues; the item supports a unique best answer without contradictions or underspecification. No medical accuracy issues; aligns with current mainstream standards on immune-related adverse events, including vedolizumab preference in hepatitis. Minimal fix: None required, as the item is unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. The clinical problem is determining the next management step for a patient with metastatic melanoma on ipilimumab/nivolumab presenting with immune-related colitis and concurrent hepatitis. Key stem clues include six watery stools daily (indicating grade 3 colitis), AST 180 U/L and ALT 220 U/L with normal bilirubin (grade 2 hepatitis), and colonoscopy showing ulcerative colitis-like changes. These drive a unique best answer: initiate high-dose prednisone (1 mg/kg), adding vedolizumab if no improvement in 3-5 days, as infliximab is contraindicated due to hepatotoxicity risk in concurrent hepatitis, per ASCO/NCCN guidelines. The most likely diagnosis is immune checkpoint inhibitor-induced colitis and hepatitis. Keyed answer C fits precisely, requiring no unstated assumptions beyond standard toxicity grading. Alternatives: A is worse due to infliximab's hepatic risk; B adds vedolizumab empirically, contrary to stepwise guidelines; D is inadequate for grade 3 severity without steroids; E uses mycophenolate, which is not first-line for colitis and more suited for refractory hepatitis. No main logical issues; the item supports a unique best answer without contradictions or underspecification. No medical accuracy issues; aligns with current mainstream standards on immune-related adverse events, including vedolizumab preference in hepatitis. Minimal fix: None required, as the item is unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251225T234023630Z_kimi-k2-thinking_seed133", "question_id": "20251225T234023630Z_kimi-k2-thinking_seed133-004", "question": "A 45-year-old man with necrotizing pancreatitis is now 3 weeks from disease onset. Contrast-enhanced CT demonstrates a 9-cm walled-off necrosis in the lesser sac with a mature, well-defined wall. ERCP confirms disconnected pancreatic duct syndrome. He is febrile to 38.5°C with WBC 15,000 cells/µL. What is the definitive management?", "options": ["Immediate percutaneous catheter drainage", "Endoscopic ultrasound-guided cystgastrostomy now", "Surgical cystgastrostomy with necrosectomy now", "Delay intervention until 4 weeks then proceed endoscopically", "Continue antibiotics and observe"], "answer": "C", "answer_index": 2, "explanation": "The 2020 revised Atlanta guidelines permit intervention when WON demonstrates a mature wall, eliminating the mandatory 4-week wait. Disconnected pancreatic duct syndrome is a surgical indication because endoscopic drainage alone is associated with 40% recurrence. Surgical cystgastrostomy with necrosectomy definitively addresses both the necrosis and ductal disruption, reducing recurrence to <10%.", "generator_model": "kimi-k2-thinking", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "General Surgery", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: K. Verdict on keyed answer: Miskeyed. The clinical problem is definitive management of suspected infected walled-off necrosis (WON) with disconnected pancreatic duct syndrome (DPDS) in a 45-year-old man 3 weeks post-necrotizing pancreatitis onset. Key stem clues driving a unique best answer: 9-cm mature-walled WON in lesser sac, ERCP-confirmed DPDS, fever (38.5°C), leukocytosis (15,000/µL), implying infected WON requiring prompt drainage. These support endoscopic intervention as first-line per current guidelines (e.g., AGA, Atlanta classification), allowing earlier action with mature wall, no mandatory 4-week delay. Most likely next step: Endoscopic ultrasound-guided cystgastrostomy (option B) for minimally invasive drainage. Keyed answer C (surgical cystgastrostomy with necrosectomy now) assumes surgery is definitive for DPDS due to lower recurrence, but this is not standard; endoscopic is preferred initially, with surgery reserved for failures. Alternatives: A worse as percutaneous is less preferred for lesser sac; D unnecessary delay despite mature wall; E inadequate for infected WON. Main logical issue: Unique best answer exists (B), but key mismatches it. Main medical accuracy issues: Item promotes surgery over endoscopic as definitive for DPDS, contradicting mainstream guidelines favoring step-up minimally invasive approaches; cited 40% endoscopic recurrence vs <10% surgical is not broadly supported for initial management. Minimal fix: Change keyed answer to B.\",\n  \"medical_accuracy_score\": 2,\n  \"logical_validity\": false,\n  \"logical_false_reason\": \"K\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K. Verdict on keyed answer: Miskeyed. The clinical problem is definitive management of suspected infected walled-off necrosis (WON) with disconnected pancreatic duct syndrome (DPDS) in a 45-year-old man 3 weeks post-necrotizing pancreatitis onset. Key stem clues driving a unique best answer: 9-cm mature-walled WON in lesser sac, ERCP-confirmed DPDS, fever (38.5°C), leukocytosis (15,000/µL), implying infected WON requiring prompt drainage. These support endoscopic intervention as first-line per current guidelines (e.g., AGA, Atlanta classification), allowing earlier action with mature wall, no mandatory 4-week delay. Most likely next step: Endoscopic ultrasound-guided cystgastrostomy (option B) for minimally invasive drainage. Keyed answer C (surgical cystgastrostomy with necrosectomy now) assumes surgery is definitive for DPDS due to lower recurrence, but this is not standard; endoscopic is preferred initially, with surgery reserved for failures. Alternatives: A worse as percutaneous is less preferred for lesser sac; D unnecessary delay despite mature wall; E inadequate for infected WON. Main logical issue: Unique best answer exists (B), but key mismatches it. Main medical accuracy issues: Item promotes surgery over endoscopic as definitive for DPDS, contradicting mainstream guidelines favoring step-up minimally invasive approaches; cited 40% endoscopic recurrence vs <10% surgical is not broadly supported for initial management. Minimal fix: Change keyed answer to B.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251225T234023630Z_kimi-k2-thinking_seed133", "question_id": "20251225T234023630Z_kimi-k2-thinking_seed133-005", "question": "A 58-year-old kidney transplant recipient (deceased donor, 8 months post-transplant) presents with rising creatinine from 1.2 to 2.1 mg/dL. Plasma BK virus PCR is 18,000 copies/mL. Allograft biopsy shows Banff class B BK virus nephropathy. Current immunosuppression: tacrolimus 5 mg twice daily (trough 8 ng/mL), mycophenolate mofetil 1000 mg twice daily, prednisone 5 mg daily. What is the first immunosuppression modification?", "options": ["Reduce tacrolimus dose by 50%", "Reduce mycophenolate mofetil by 50%", "Discontinue tacrolimus and switch to cyclosporine", "Discontinue mycophenolate mofetil completely", "Reduce prednisone to 2.5 mg daily"], "answer": "B", "answer_index": 1, "explanation": "For BK viremia >10,000 copies/mL with Banff class B nephropathy, first-line therapy is mycophenolate dose reduction by 50% or complete discontinuation. Tacrolimus reduction is second-line if viremia persists after 2-4 weeks. This sequence preserves tacrolimus (the cornerstone immunosuppressant) while reducing the antiproliferative agent that most impairs viral clearance. Steroids should not be reduced initially.", "generator_model": "kimi-k2-thinking", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Urology", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: M (primary; secondary U). Verdict on keyed answer: Not uniquely determinable. Key stem clues that drive (or fail to drive) a unique best answer: 58-year-old kidney transplant recipient with rising creatinine (1.2 to 2.1 mg/dL), plasma BK PCR 18,000 copies/mL, Banff class B BK nephropathy, on tacrolimus (trough 8 ng/mL), MMF 1000 mg BID, prednisone 5 mg daily; question seeks first immunosuppression modification. Main logical issue(s): Stem and options allow both B (reduce MMF by 50%) and D (discontinue MMF completely) as equally defensible first-line actions per provided rationale and standard guidelines (e.g., AST/KDIGO suggesting MMF reduction or discontinuation for BK nephropathy); lacks discriminating detail (e.g., severity nuance or protocol preference) to favor one uniquely, making it underspecified leading to multiple defensible answers. Main medical accuracy issue(s): None; implied management aligns with consensus for initial reduction of antiproliferative agent in BK viremia/nephropathy to facilitate viral clearance while preserving calcineurin inhibitor. Minimal fix: Add to stem 'with moderate graft dysfunction and no prior adjustments' to emphasize stepwise reduction, making B the unique best over D.\",\n  \"medical_accuracy_score\": 4,\n  \"logical_validity\": false,\n  \"logical_false_reason\": \"M\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (primary; secondary U). Verdict on keyed answer: Not uniquely determinable. Key stem clues that drive (or fail to drive) a unique best answer: 58-year-old kidney transplant recipient with rising creatinine (1.2 to 2.1 mg/dL), plasma BK PCR 18,000 copies/mL, Banff class B BK nephropathy, on tacrolimus (trough 8 ng/mL), MMF 1000 mg BID, prednisone 5 mg daily; question seeks first immunosuppression modification. Main logical issue(s): Stem and options allow both B (reduce MMF by 50%) and D (discontinue MMF completely) as equally defensible first-line actions per provided rationale and standard guidelines (e.g., AST/KDIGO suggesting MMF reduction or discontinuation for BK nephropathy); lacks discriminating detail (e.g., severity nuance or protocol preference) to favor one uniquely, making it underspecified leading to multiple defensible answers. Main medical accuracy issue(s): None; implied management aligns with consensus for initial reduction of antiproliferative agent in BK viremia/nephropathy to facilitate viral clearance while preserving calcineurin inhibitor. Minimal fix: Add to stem 'with moderate graft dysfunction and no prior adjustments' to emphasize stepwise reduction, making B the unique best over D.", "medical_accuracy_score": 4, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251225T234023630Z_kimi-k2-thinking_seed133", "question_id": "20251225T234023630Z_kimi-k2-thinking_seed133-006", "question": "A 62-year-old man with metastatic melanoma receives axicabtagene ciloleucel. On day 7 post-infusion, he develops confusion, expressive aphasia, and asterixis. He has a low-grade fever (37.8°C) only. ICE score is 8/10. EEG demonstrates triphasic waves. Brain MRI is normal. What is the immediate management?", "options": ["Tocilizumab 8 mg/kg intravenously once", "Dexamethasone 10 mg intravenously every 6 hours", "Methylprednisolone 1 g intravenously daily", "Tocilizumab plus dexamethasone 10 mg every 6 hours", "Supportive care with scheduled haloperidol"], "answer": "B", "answer_index": 1, "explanation": "An ICE score of 8 indicates grade 2 immune effector cell-associated neurotoxicity syndrome (ICANS), which requires dexamethasone 10 mg IV q6h. Tocilizumab is indicated for cytokine release syndrome (CRS), not ICANS, and is unnecessary for grade 1 CRS. High-dose methylprednisolone is reserved for grade ≥3 ICANS. The EEG findings are characteristic but do not escalate management beyond standard ICANS algorithms.", "generator_model": "kimi-k2-thinking", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Medical Oncology", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include day 7 post-axicabtagene ciloleucel infusion, symptoms of confusion, expressive aphasia, and asterixis, low-grade fever (37.8°C) as the only CRS sign (grade 1), ICE score 8/10 (grade 2 ICANS), triphasic waves on EEG (consistent with ICANS), and normal MRI (ruling out structural causes). These support grade 2 ICANS management per ASTCT guidelines, favoring dexamethasone 10 mg IV q6h without tocilizumab, as CRS is mild. Main logical issue(s): none; the vignette provides sufficient details for discrimination, with no contradictions or underspecification leading to multiple defensible answers. Options are well-differentiated: A (tocilizumab alone) targets CRS not ICANS; C (high-dose methylprednisolone) is for grade ≥3; D adds unnecessary tocilizumab for grade 1 CRS; E (supportive care) lacks specific ICANS therapy. Main medical accuracy issue(s): none; aligns with current ASTCT consensus on CAR-T toxicities, including ICANS grading (ICE 7-9 = grade 2) and management (dexamethasone for grade 2, reserve tocilizumab for CRS ≥2, high-dose steroids for severe cases). EEG findings are appropriately characteristic without altering management. Minimal fix: none needed; item is unambiguous and accurate as written.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include day 7 post-axicabtagene ciloleucel infusion, symptoms of confusion, expressive aphasia, and asterixis, low-grade fever (37.8°C) as the only CRS sign (grade 1), ICE score 8/10 (grade 2 ICANS), triphasic waves on EEG (consistent with ICANS), and normal MRI (ruling out structural causes). These support grade 2 ICANS management per ASTCT guidelines, favoring dexamethasone 10 mg IV q6h without tocilizumab, as CRS is mild. Main logical issue(s): none; the vignette provides sufficient details for discrimination, with no contradictions or underspecification leading to multiple defensible answers. Options are well-differentiated: A (tocilizumab alone) targets CRS not ICANS; C (high-dose methylprednisolone) is for grade ≥3; D adds unnecessary tocilizumab for grade 1 CRS; E (supportive care) lacks specific ICANS therapy. Main medical accuracy issue(s): none; aligns with current ASTCT consensus on CAR-T toxicities, including ICANS grading (ICE 7-9 = grade 2) and management (dexamethasone for grade 2, reserve tocilizumab for CRS ≥2, high-dose steroids for severe cases). EEG findings are appropriately characteristic without altering management. Minimal fix: none needed; item is unambiguous and accurate as written.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}]